A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer
NCT07483307
This study is recruiting at 7 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to look at how effective neoadjuvant (before surgery) endocrine therapy (NET) is in participants with invasive lobular carcinoma (ILC) who have breast-conserving surgery (BCS). The main purpose of the study is to see if NET reduces the chance of having cancer cells at the edges of tissue removed during surgery (positive margins).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
- HER2-negative Breast Cancer
- HER2 Negative Breast Carcinoma
- ER+ Breast Cancer
- Lobular Breast Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 50 years and older
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Last updated on ClinicalTrials.gov
- June 4, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New Jersey · 3
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, NJ
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, NJ
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, NJ
New York · 4
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) · Commack, NY
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, NY
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) · New York, NY
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) · Uniondale, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.